Basilea Wins CARB-X Funding Boost for First-in-Human Trial of Novel Antibiotic BAL2420

Basilea Pharmaceutica ( (CH:BSLN) ) has issued an announcement.

Basilea Pharmaceutica has secured an additional USD 6 million in non‑dilutive funding from CARB-X to support a first‑in‑human Phase 1 trial of its novel antibiotic BAL2420, an LptA inhibitor targeting gram‑negative bacteria. The trial has begun, with the first subject dosed in March 2026, marking a key step in advancing one of the few new antibiotic classes in clinical development against multidrug‑resistant pathogens prioritized by global health authorities.

The continued CARB-X backing, which has supported BAL2420 from hit‑to‑lead stages to early clinical testing, underscores the project’s potential to address urgent unmet medical needs in severe infections caused by Enterobacteriaceae, including carbapenem‑resistant strains. For Basilea, the funding reduces development burden while reinforcing its position in the global fight against antimicrobial resistance and its strategy to expand a pipeline of innovative anti‑infective therapies.

The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF69.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.

More about Basilea Pharmaceutica

Basilea Pharmaceutica AG is a Switzerland‑based biopharmaceutical company focused on discovering, developing and marketing medicines for severe bacterial and fungal infections. It already commercializes the hospital‑use drugs Cresemba for invasive fungal infections and Zevtera for bacterial infections, and maintains a portfolio of preclinical and clinical anti‑infective programs, with its shares listed on SIX Swiss Exchange under the ticker BSLN.

Average Trading Volume: 37,098

Technical Sentiment Signal: Buy

Current Market Cap: CHF645.8M

For an in-depth examination of BSLN stock, go to TipRanks’ Overview page.